Literature DB >> 5743

Dystonic reactions following neuroleptics: time course and proposed mechanisms.

D L Garver, D M Davis, H Dekirmenjian, S Ericksen, L Gosenfeld, J Haraszti.   

Abstract

The occurrence of acute dystonic reactions was studied relative to drug pharmacokinetic parameters following a single dose of the phenothiazine, butaperazine. Dystonias occurred more than one half-life from peak butaperazine levels, 23 to 56 h after drug administration. The authors postulate that the appearance of dystonias on falling plasma concentrations may be due to disruption of dopaminergic-cholinergic balance caused by differential antidopaminergic and anticholinergic potencies of the drug.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 5743     DOI: 10.1007/BF00735822

Source DB:  PubMed          Journal:  Psychopharmacologia


  4 in total

Review 1.  Dopamine receptors in the brain.

Authors:  L L Iversen
Journal:  Science       Date:  1975-06-13       Impact factor: 47.728

2.  Drugs, neurotransmitters, and schizophrenia.

Authors:  S H Snyder; S P Banerjee; H I Yamamura; D Greenberg
Journal:  Science       Date:  1974-06-21       Impact factor: 47.728

3.  A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta.

Authors:  R M Ferris; F L Tang; R A Maxwell
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

4.  The physiological disposition of chlorpromazine in the rat and dog.

Authors:  S H Curry; J E Derr; H M Maling
Journal:  Proc Soc Exp Biol Med       Date:  1970-05
  4 in total
  13 in total

1.  Antipsychotic-induced movement disorders: evaluation and treatment.

Authors:  Maju Mathews; Sylvia Gratz; Babatunde Adetunji; Vinu George; Manu Mathews; Biju Basil
Journal:  Psychiatry (Edgmont)       Date:  2005-03

Review 2.  Diagnosis and management of acute movement disorders.

Authors:  D Dressler; R Benecke
Journal:  J Neurol       Date:  2005-10-10       Impact factor: 4.849

Review 3.  Mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine D2 receptor inhibition.

Authors:  R D Todd; J S Perlmutter
Journal:  Mol Neurobiol       Date:  1998-04       Impact factor: 5.590

Review 4.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 5.  Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management.

Authors:  Toshihito Suzuki; Hisashi Matsuzaka
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat.

Authors:  J D Salamone; C J Johnson; L D McCullough; R E Steinpreis
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?

Authors:  Morvarid Karimi; Stephen M Moerlein; Tom O Videen; Robert R Luedtke; Michelle Taylor; Robert H Mach; Joel S Perlmutter
Journal:  Mov Disord       Date:  2010-10-19       Impact factor: 10.338

8.  Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia.

Authors:  J S Perlmutter; M K Stambuk; J Markham; K J Black; L McGee-Minnich; J Jankovic; S M Moerlein
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

9.  Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains.

Authors:  P Collins; C L Broekkamp; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Dystonic reactions and the pharmacokinetics of metoclopramide in children.

Authors:  D N Bateman; A W Craft; E Nicholson; A D Pearson
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.